A Phase II Trial of Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) With Weekly Protein Bound Paclitaxel (Abraxane) as Chemoimmunotherapy for Platinum- Refractory/Resistant Epithelial Ovarian, Primary Peritoneal and Fallopian Tube Cancer.
Phase of Trial: Phase II
Latest Information Update: 30 Aug 2017
At a glance
- Drugs Sargramostim (Primary) ; Paclitaxel
- Indications Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Therapeutic Use
- 31 Aug 2018 Biomarkers information updated
- 02 Jun 2015 Results assessing immune responses presented at the 51st Annual Meeting of the American Society of Clinical Oncology.
- 10 Apr 2012 Additional trial identifier identified as reported by ClinicalTrials.gov.